Daiichi Sankyo's Factor Xa Inhibitor Edoxaban Clears Phase III Hurdle - A Major Threat To Xarelto And Eliquis
There are no Transcripts on DSKYF.
We currently have no Breaking News on this stock.
There are no StockTalks on this stock yet.
DSKYF vs. ETF Alternatives
Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo delivers innovative products that enhance the lives of millions of people around the world. Our recent successes include the antihypertensive agent olmesartan (Olmetec), launched in 2002 by... More
Other News & PR